Efficiency of topical imiquimod 5% cream in the management of chronic radiation dermatitis with multiple neoplasias.
The immune response modifier imiquimod 5% cream (Aldara) was locally applied to an extensive thoracic chronic radiation dermatitis for 2 weeks on a once daily basis. After moderate to severe irritative reactions with erythema and crusted erosions, areas cleared up within 4 weeks. The patient has now been in complete remission for 2 years.
Sachse
Michael M
MM
Department of Dermatology, Skin Cancer Centre Charité, Charité University Hospital, Schumannstr. 20/21, 10117 Berlin, Germany.
Zimmermann
Jutta
J
Bahmer
Friedrich A
FA
D000287:Administration, Topical; D000634:Aminoquinolines / Q000627:therapeutic use*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000473:pathology / Q000532:radiotherapy*; D011855:Radiodermatitis / Q000175:diagnosis* / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000634:Aminoquinolines; D000077271:Imiquimod